VCA shareholders have the option to file a class action lawsuit to ensure the board of directors obtains the best possible price for shareholders and the disclosure of material information. VCA shareholders interested in information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, firstname.lastname@example.org, or via the shareholder information form on the firm's website.Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law. The law firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Attorney Advertising. Past results do not guarantee a similar outcome.
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of VCA Inc. (NASDAQGS: WOOF) by Mars, Incorporated (Private). On January 9, 2017, the two companies announced the signing of a definitive merger agreement pursuant to which Mars will acquire VCA. Under the terms of the agreement, VCA shareholders will receive $93.00 for each share of VCA common stock. View this information on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/vca-inc Is the Proposed Acquisition Best for VCA and Its Shareholders? Robbins Arroyo LLP's investigation focuses on whether the board of directors at VCA is undertaking a fair process to obtain maximum value and adequately compensate its shareholders. On October 26, 2016, VCA reported strong earnings results for its third quarter 2016. VCA reported revenue of $656.9 million for the three months ended September 30, 2016, a 19.1% increase over the same period of the prior year. VCA also reported diluted earnings per share of $0.71 for the three months ended September 30, 2016, a 6.0% increase from the same period of the prior year. VCA has also beaten analyst estimates for adjusted net income, revenue, and adjusted earnings per share in three of the past four consecutive quarters. In commenting on these results, VCA Chief Executive Officer and Chairman of the board Bob Antin remarked, "We continue to experience healthy organic revenue growth and increasing gross margins in both our core Animal Hospital and Laboratory businesses. Given our results relative to our expectations and our future acquisition pipeline, we remain optimistic with respect to our results for the full year ended December 31, 2016." In light of these facts, Robbins Arroyo LLP is examining VCA's board of directors' decision to sell the company now rather than allow shareholders to continue to participate in the company's continued success and future growth prospects.